Heterogeneity in breast cancer.

By K. Polyak. Journal of Clinical Investigation, 2011

946 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/d628e6aa5cc6321bdd1c54c1c1e7da8229354611

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Oncology

Citations in the corpus

Loss of FBP1 by Snail-mediated Repression Provides Metabolic Advantages in Basal-like Breast Cancer (2013, neutral): “BLBC is defined by expression of markers characteristic of basal/myoepithelial cells and is identified as a subgroup of breast cancers that may originate from undifferentiated stem cells (Polyak, 2011).”
MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer (2015, background): “BC is a heterogeneous disease with several morphological appearances, molecular features, behaviors, and response to therapy [143, 144].”
Deep Convolutional Neural Networks Enable Discrimination of Heterogeneous Digital Pathology Images (2017, background): “, a high degree of genetic and phenotypic diversity exists “within tumors” (intra-tumor) and “among tumors” (inter-tumor) (Polyak, 2011).”
Unsupervised spatially embedded deep representation of spatial transcriptomics (2021, methodology): “In this example, we tested SEDR on the 10 × Genomics Visium spatial transcrip-tomics acquired data for human breast cancer, which is known for its high intratumoral and intertumoral differences [47].”
Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis (2018, background): “The tumor microenvironment may also contribute significantly to tumor heterogeneity as the tumor microenvironment includes not only cancer cells but also, immune cells, inflammatory cells, vascular cells, lymphatic cells, fibroblasts, and fibrous tissue, all of which impact the cancer’s response to ”
Artificial Intelligence for Clinical Oncology (2021, background): “As our biological perspective has evolved, we now know that cancer is made up of thousands of distinct entities that will follow different trajectories, each with different treatment strategies (Dagogo-Jack and Shaw, 2018; Polyak, 2011).”